121. 脳内鉄沈着神経変性症 Disease details / Clinical trials / Drug dev / DR info /

臨床試験数 : 30 / 薬物数 : 26 - (DrugBank : 5) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 106

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Balance and coordination
   Kirsehir Ahi Evran Universitesi
      2023   -   NCT05678790   Turkey
BAY 80-6946
   UNICANCER
      2016   Phase 1;Phase 2   EUCTR2015-004340-19-FR   France
Bpan patients
   Hospices Civils de Lyon
      2023   -   NCT05954494   France
Copanlisib
   UNICANCER
      2016   Phase 1;Phase 2   EUCTR2015-004340-19-FR   France
Deferiprone
   AZIENDA OSPEDALIERA OSPEDALI GALLIERA
      2008   -   EUCTR2008-005206-39-IT   Italy
   Chiesi Canada Corp
      2016   -   NCT02635841   -
   Ente Ospedaliero Ospedali Galliera
      2008   Phase 2   NCT00907283   Italy
   ISTITUTO NEUROLOGICO CARLO BESTA
      2008   -   EUCTR2008-003059-56-IT   Italy
Deferiprone 80 MG/ML oral solution
   APOTEX EUROPE B.V.
      -   Phase 3   EUCTR2014-001427-79-IT   Germany;Italy;United Kingdom;United States
   ApoPharma Inc
      2015   Phase 3   EUCTR2014-001427-79-GB   Germany;Italy;United Kingdom;United States
      2013   Phase 3   EUCTR2012-000845-11-GB   Germany;Italy;Poland;United Kingdom;United States
   ApoPharma Inc.
      2015   Phase 3   EUCTR2014-001427-79-DE   Germany;Italy;United Kingdom;United States
      2013   Phase 3   EUCTR2012-000845-11-IT   Germany;Italy;Poland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000845-11-DE   Germany;Italy;Poland;United Kingdom;United States
Deferiprone oral solution
   ApoPharma
      2014   Phase 3   NCT02174848   Germany;Italy;United Kingdom;United States
      2012   Phase 3   NCT01741532   Germany;Italy;Poland;United Kingdom;United States
Desipramine
   Duke University
      2019   Phase 4   NCT03726996   United States
Erbitux
   UNICANCER
      2016   Phase 1;Phase 2   EUCTR2015-004340-19-FR   France
Establishment OF mitochondrial markers
   University Hospital, Bordeaux
      2018   -   NCT05615571   France
EX-vivo approach concerning 25 patients
   University Hospital, Bordeaux
      2023   -   NCT05696912   France
Ferriprox
   AZIENDA OSPEDALIERA OSPEDALI GALLIERA
      2008   -   EUCTR2008-005206-39-IT   Italy
   ApoPharma Inc
      2015   Phase 3   EUCTR2014-001427-79-GB   Germany;Italy;United Kingdom;United States
      2013   Phase 3   EUCTR2012-000845-11-GB   Germany;Italy;Poland;United Kingdom;United States
Ferriprox*100CPR RIV 500MG
   ISTITUTO NEUROLOGICO CARLO BESTA
      2008   -   EUCTR2008-003059-56-IT   Italy
Fosmetpantotenate
   Retrophin, Inc.
      2017   Phase 3   EUCTR2016-001955-29-ES   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
   Travere Therapeutics, Inc.
      2017   Phase 3   NCT03041116   Canada;Czechia;France;Germany;Italy;Norway;Poland;Spain;United States
Fosmetpantotenate drug substance
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-001955-29-FR   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001955-29-GB   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Serbia;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001955-29-CZ   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2016-001955-29-PL   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2016-001955-29-NO   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2016-001955-29-DE   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
Fosmetpantotenato
   RETROPHIN, INC
      2017   Phase 3   EUCTR2016-001955-29-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
Hematopoetic stem cell transplantation
   University of Pittsburgh
      2012   -   NCT03333200   United States
IN-vitro approach concerning 25 patients
   University Hospital, Bordeaux
      2023   -   NCT05696912   France
Mobilization
   Kirsehir Ahi Evran Universitesi
      2023   -   NCT05678790   Turkey
Muscle strengthening
   Kirsehir Ahi Evran Universitesi
      2023   -   NCT05678790   Turkey
Palliative care
   University of Pittsburgh
      2012   -   NCT03333200   United States
Pantethine
   Department of Pediatrics, Peking University First Hospital
      2018   -   ChiCTR1900021076   China
Passive stretching
   Kirsehir Ahi Evran Universitesi
      2023   -   NCT05678790   Turkey
RE-024
   RETROPHIN, INC
      2017   Phase 3   EUCTR2016-001955-29-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-001955-29-FR   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001955-29-GB   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Serbia;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001955-29-ES   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001955-29-CZ   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2016-001955-29-PL   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2016-001955-29-NO   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2016-001955-29-DE   Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States
   Travere Therapeutics, Inc.
      2017   Phase 3   NCT03041116   Canada;Czechia;France;Germany;Italy;Norway;Poland;Spain;United States
RT001
   Retrotope, Inc.
      2018   Phase 2/Phase 3   NCT03570931   United States
Sequencing tests
   University Hospital, Bordeaux
      2018   -   NCT05615571   France